Synonyms: MMV000147
Compound class:
Synthetic organic
Comment: The antifolate compound P218 is a potent and selective inhibitor of P. falciparum bifunctional dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) and was designed to overcome the emergence of parasite resistance to this class of antimalarial compound [7].
The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
The interaction table below provides data from whole cell assays and gives the antiparasite activity of P218 against a number of Plasmodium lifecycle stages. The results include an evaluation of asexual blood stage activity, with high potency observed against both a wild-type and a clinically relevant pyrimethamine-resistant strain (PfV1/S) [7]. The compound is also active against hepatic schizonts [4] and has transmission blocking potential, inhibiting exflagellation in both wild-type PfNF54 (IC50 of 4 nM) and NF54-4mutPfdhfr, a transgenic strain with quadruple PfDHFR mutations (IC50 of 11 nM) [3]. |
Whole organism assay data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click on species/strain names for details | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|